Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Rupert Bauersachs"'
Autor:
Eugenio Stabile, Sebastian Debus, Lucia Mazzolai, Oliver Schlager, Jean-Philippe Collet, Christine Espinola-Klein, Heinz Drexel, Basil S. Lewis, Marco Roffi, Marco De Carlo, Rupert Bauersachs, Henrik Sillesen, Victor Aboyans, José F. Rodríguez Palomares, Marianne Brodmann, Dirk Sibbing
Publikováno v:
European Heart Journal. 42:4013-4024
The aim of this collaborative document is to provide an update for clinicians on best antithrombotic strategies in patients with aortic and/or peripheral arterial diseases. Antithrombotic therapy is a pillar of optimal medical treatment for these pat
Autor:
Rupert Bauersachs, Walter Ageno, Gualberto Gussoni, Ander Cohen, Cecilia Becattini, Giancarlo Agnelli, Maria Cristina Vedovati, Menno V. Huisman
Publikováno v:
Thrombosis and Haemostasis
Thrombosis and Haemostasis. GEORG THIEME VERLAG KG
Thrombosis and Haemostasis. GEORG THIEME VERLAG KG
Background Direct oral anticoagulants are recommended for the treatment of cancer-associated thrombosis (CAT) as an alternative to low-molecular-weight heparin (LMWH), but an increased bleeding risk in patients with gastrointestinal cancer was report
Autor:
Ajay K. Kakkar, Rodney Hughes, Mark Levine, Anna Falanga, Rupert Bauersachs, Alex Kahney, John Wong, Gloria Kayani
Publikováno v:
The Oncologist
Background Fundamental Research in Oncology and Thrombosis (FRONTLINE) is a global survey of physicians' perceptions and practice in the management of venous thromboembolism (VTE) in patients with cancer. Materials and Methods The present survey, FRO
Autor:
Manesh R. Patel, Sigrid Nikol, Rupert Bauersachs, Sebastian Debus, E. Hope Weissler, Victor Aboyans, W. Schuyler Jones, Marianne Brodmann
Publikováno v:
JACC Cardiovasc Interv
Evidence for antithrombotic treatment following lower extremity revascularization (LER) for peripheral artery disease (PAD) is limited, leading to weak and conflicting guideline recommendations and heterogeneous practice patterns. This variability in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f39345bb1284a4f9237b5f74929a8a0
https://europepmc.org/articles/PMC10122189/
https://europepmc.org/articles/PMC10122189/
Direct oral anticoagulants for the treatment of pulmonary embolism in patients with renal impairment
Publikováno v:
Thrombosis research. 204
Pulmonary embolism (PE) is associated with adverse outcomes and substantial morbidity and mortality. Patients with PE often have renal impairment because of shared risk factors and close links between the renal and cardiovascular systems. Furthermore
Autor:
Victor Aboyans, Francesco Violi, Jean-Baptiste Ricco, Manesh R. Patel, Jackie Bosch, Eike Sebastian Debus, Peter Verhamme, Jean-François Tanguay, Rupert Bauersachs, Daniele Pastori, Lucia Mazzolai, Sonia S. Anand, John W. Eikelboom, Mark R. Nehler, Sigrid Nikol
Publikováno v:
Thrombosis and Haemostasis
Thrombosis and Haemostasis, Schattauer, 2019
Thrombosis and Haemostasis, Schattauer, 2019
The most common causes of ischaemic stroke are represented by carotid artery atherosclerotic disease (CAAD) and atrial fibrillation. While oral anticoagulants substantially reduce the incidence of thromboembolic stroke (< 1%/year), the rate of ischae
Autor:
Anselm K. Gitt, Giancarlo Agnelli, Stefan N. Willich, Eva-Maria Fronk, Manuel Monreal, Rupert Bauersachs, Alexander T. Cohen, Peter Bramlage, Petra Laeis, Patrick Mismetti
Publikováno v:
Thrombosis Research. 157:181-188
Introduction The appropriate strategy for initiating oral anticoagulant (OAC) therapy after an acute venous thromboembolism (VTE) depends on the intermediate-term anticoagulant to be used. While heparin bridging to vitamin K antagonists (VKA) is requ
Autor:
Jan Beyer-Westendorf, Peter Verhamme, Anthony Maraveyas, Rupert Bauersachs, Jeffrey I. Weitz, Mark Crowther, Hanno Riess, Annie M. Young
Publikováno v:
Critical Reviews in Oncology/Hematology. 157:103125
Low-molecular-weight heparin (LMWH) therapy is recommended over vitamin K antagonists (VKAs) for the treatment of cancer-associated thrombosis (CAT) and extended therapy is recommended in those with active cancer to prevent recurrent thrombosis. Howe
Publikováno v:
Thrombosis Research, Vol. 151, No Suppl. 1 (2017) pp. S21-S29
Venous thromboembolism (VTE) is a major common complication in cancer patients. Risk-adapted thromboprophylaxis and antithrombotic therapy for patients diagnosed with VTE can reduce the recurrence of VTE events. Thrombotic risk varies according to ca
Publikováno v:
Martínez-Zapata, M J, Mathioudakis, A, Mousa, S & Bauersachs, R 2017, ' Tinzaparin for Long-Term Treatment of Venous Thromboembolism in Patients With Cancer : A Systematic Review and Meta-Analysis ', Clinical and Applied Thrombosis / Hemostasis . https://doi.org/10.1177/1076029617696581
Clinical and Applied Thrombosis/Hemostasis
Clinical and Applied Thrombosis/Hemostasis
Patients with cancer are at increased risk of recurrent venous thromboembolism (VTE) and bleeding. Thus, long-term treatment with anticoagulants for secondary prevention is challenging. The objective of this review was to evaluate current evidence on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::521a7f4d8c8e04ead8f731f97d08ece9
https://doi.org/10.1177/1076029617696581
https://doi.org/10.1177/1076029617696581